TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: A phase 2, randomised, double-blind, placebo-controlled trial

The Lancet

Volumn 379, Issue 9824, 2012, Pages 1403-1411

  Burant, Charles F ^a   Viswanathan, Prabhakar ^b   Marcinak, John ^b   Cao, Charlie ^b   Vakilynejad, Majid ^b   Xie, Benhuai ^b   Leifke, Eckhard ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b TAKEDA PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; GLIMEPIRIDE; HEMOGLOBIN A1C; METFORMIN; PLACEBO; TAK 875; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHOLELITHIASIS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG TARGETING; DRUG WITHDRAWAL; FEMALE; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THERAPY EFFECT; TREATMENT OUTCOME;

EID: 84859625938     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(11)61879-5     Document Type: Article

References (27)

1. PA Insel, CM Tang, I Hahntow, MC Michel Impact of GPCRs in clinical medicine: monogenic diseases, genetic variants and drug targets Biochim Biophys Acta 1768 2007 994 1005
2. DK Vassilatis, JG Hohmann, H Zeng et al. The G-protein-coupled receptor repertoires of human and mouse Proc Natl Acad Sci USA 100 2003 4903 4908
3. J Cornish, A MacGibbon, JM Lin et al. Modulation of osteoclastogenesis by fatty acids Endocrinology 149 2008 5688 5695
4. MA Hidalgo, C Nahuelpan, C Manosalva et al. Oleic acid induces intracellular calcium mobilization, MAPK phosphorylation, superoxide production and granule release in bovine neutrophils Biochem Biophys Res Commun 409 2011 280 286
5. S Edfalk, P Steneberg, H Edlund Gpr40 is expressed in enteroendocrine cells and mediates free fatty acid stimulation of incretin secretion Diabetes 57 2008 2280 2287
6. CP Briscoe, M Tadayyon, JL Andrews et al. The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids J Biol Chem 278 2003 11303 11311
7. Y Itoh, Y Kawamata, M Harada et al. Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40 Nature 422 2003 173 176
8. J Schmidt, K Liebscher, N Merten et al. Conjugated linoleic acids mediate insulin release through islet G protein-coupled receptor FFA1/GPR40 J Biol Chem 286 2011 11890 11894
9. K Nagasumi, R Esaki, K Iwachidow et al. Overexpression of GPR40 in pancreatic beta-cells augments glucose-stimulated insulin secretion and improves glucose tolerance in normal and diabetic mice Diabetes 58 2009 1067 1076
10. Y Itoh, S Hinuma GPR40, a free fatty acid receptor on pancreatic beta cells, regulates insulin secretion Hepatol Res 33 2005 171 173
11. B Ahren Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes Nat Rev Drug Discov 8 2009 369 385
12. GG Holz Epac: A new cAMP-binding protein in support of glucagon-like peptide-1 receptor-mediated signal transduction in the pancreatic beta-cell Diabetes 53 2004 5 13
13. T Alquier, V Poitout GPR40: good cop, bad cop? Diabetes 58 2009 1035 1036
14. Y Tsujihata, R Itou, M Suzuki et al. TAK-875, a novel, orally available GPR40 agonist, augments, glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats Diabetes 59 suppl 1 2010 A165 (abstr).
15. K Takeuchi, Y Tsujihata, R Ito, M Suzuki, A Harada, M Hazama A selective GPR40 agonist, TAK-875, stimulates glucose-dependent insulin secretion without beta cell toxicity and decreases glycosylated hemoglobin levels in diabetic rats Diabetologia 53 suppl 1 2010 S353 (abstr).
16. E Leifke, J Wu, P Viswanathan, MS Kipnes, M Vakilynejad Safety, tolerability, pharmacokinetics and pharmacodynamics of TAK-875, a novel GPR40 agonist, following once-daily oral administration for 2 weeks in type 2 diabetic patients [abstract 414-PP] Diabetes 60 suppl 1 2011 A114 A1A5
17. Matsuno K, Hirayama M, Araki T, Dote N, Kondo T, Nakamura K. Pharmacokinetics, safety and tolerability of single and multiple doses of TAK-875, a novel GPR40 agonist, in Japanese healthy male subjects. American Diabetes Association 70th Scientific Sessions; June 25-29, 2010; Orlando, FL, USA.
18. H Naik, M Vakilynejad, J Wu et al. Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of the GPR40 agonist TAK-875: results from a double blind, placebo controlled single oral dose-rising study in healthy volunteers J Clin Pharmacol 2011 10.1177/0091270011409230 published online May 24.
19. US Food and Drug Administration. Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Guidance for Industry: Drug-Induced Liver Injury - Premarketing Clinical Evaluation 2009.
20. M Matsuda, RA DeFronzo Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp Diabetes Care 22 1999 1462 1470
21. MA Abdul-Ghani, M Matsuda, R Jani et al. The relationship between fasting hyperglycemia and insulin secretion in subjects with normal or impaired glucose tolerance Am J Physiol Endocrinol Metab 295 2008 E401 E406
22. UA Shukla, EM Chi, KH Lehr Glimepiride pharmacokinetics in obese versus non-obese diabetic patients Ann Pharmacother 38 2004 30 35
23. AH Barnett, S Cradock, M Fisher, G Hall, E Hughes, A Middleton Key considerations around the risks and consequences of hypoglycaemia in people with type 2 diabetes Int J Clin Pract 64 2010 1121 1129
24. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet 352 1998 837 853
25. DR Whiting, L Guariguata, C Weil, J Shaw IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030 Diabetes Res Clin Pract 94 2011 311 321
26. RA DeFronzo Current issues in the treatment of type 2 diabetes. Overview of newer agents: where treatment is going Am J Med 123 3 suppl 2010 S38 S48
27. AA Tahrani, CJ Bailey, S Del Prato, AH Barnett Management of type 2 diabetes: new and future developments in treatment Lancet 378 2011 182 197